Explore
Validate
Learn
Western blot
ELISAAntibody data
- Antibody Data
- Antigen structure
- References [4]
- Comments [0]
- Validations
- Western blot [1]
- Immunocytochemistry [1]
- Immunohistochemistry [1]
Submit
Validation data
Reference
Comment
Report error
- Product number
- ABIN955177 - Provider product page
- Provider
- antibodies-online
- Product name
- anti-Transforming Growth Factor, beta Receptor II (70/80kDa) (TGFBR2) (N-Term) antibody
- Antibody type
- Polyclonal
- Antigen
- Other
- Reactivity
- Human, Mouse
- Host
- Rabbit
- Vial size
- 0.1 mg
Submitted references Cigarette smoke-induced Egr-1 represses T beta R-II expression in human skin dermal fibroblasts.
Variation at the NFATC2 locus increases the risk of thiazolidinedione-induced edema in the Diabetes REduction Assessment with ramipril and rosiglitazone Medication (DREAM) study.
Molecular anatomy of breast cancer stroma and its prognostic value in estrogen receptor-positive and -negative cancers.
TGFBR2 mutations alter smooth muscle cell phenotype and predispose to thoracic aortic aneurysms and dissections.
Kim JN, Jeong JT, Jeong SH, Kim SA, Lee KG, Shin JB, Kye YC, Son SW
Toxicology 2010 Sep 10;275(1-3):29-35
Toxicology 2010 Sep 10;275(1-3):29-35
Variation at the NFATC2 locus increases the risk of thiazolidinedione-induced edema in the Diabetes REduction Assessment with ramipril and rosiglitazone Medication (DREAM) study.
Bailey SD, Xie C, Do R, Montpetit A, Diaz R, Mohan V, Keavney B, Yusuf S, Gerstein HC, Engert JC, Anand S, DREAM investigators
Diabetes care 2010 Oct;33(10):2250-3
Diabetes care 2010 Oct;33(10):2250-3
Molecular anatomy of breast cancer stroma and its prognostic value in estrogen receptor-positive and -negative cancers.
Bianchini G, Qi Y, Alvarez RH, Iwamoto T, Coutant C, Ibrahim NK, Valero V, Cristofanilli M, Green MC, Radvanyi L, Hatzis C, Hortobagyi GN, Andre F, Gianni L, Symmans WF, Pusztai L
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2010 Oct 1;28(28):4316-23
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2010 Oct 1;28(28):4316-23
TGFBR2 mutations alter smooth muscle cell phenotype and predispose to thoracic aortic aneurysms and dissections.
Inamoto S, Kwartler CS, Lafont AL, Liang YY, Fadulu VT, Duraisamy S, Willing M, Estrera A, Safi H, Hannibal MC, Carey J, Wiktorowicz J, Tan FK, Feng XH, Pannu H, Milewicz DM
Cardiovascular research 2010 Dec 1;88(3):520-9
Cardiovascular research 2010 Dec 1;88(3):520-9
No comments: Submit comment
Supportive validation
- Submitted by
- antibodies-online (provider)
- Main image
- Experimental details
- TGFBR2 Antibody (N-term) (AP54233PU-N) western blot analysis in mouse lung tissue lysates (35 μg/lane). This demonstrates the TGFBR2 antibody detected the TGFBR2 protein (arrow).
Supportive validation
- Submitted by
- antibodies-online (provider)
- Main image
- Experimental details
- Confocal immunofluorescent analysis of TGFBR2 Antibody (N-term) (AP54233PU-N) with HepG2 cell followed by Alexa Fluor 488-conjugated goat anti-rabbit lgG (green). DAPI was used to stain the cell nuclear (blue).
Supportive validation
- Submitted by
- antibodies-online (provider)
- Main image
- Experimental details
- TGFBR2 Antibody (N-term) (AP54233PU-N)immunohistochemistry analysis in formalin fixed and paraffin embedded human placenta tissue followed by peroxidase conjugation of the secondary antibody and DAB staining. This data demonstrates the use of TGFBR2 Antibody (N-term) for immunohistochemistry. Clinical relevance has not been evaluated.
